Medy-Tox Inc. announces an Equity Buyback for 10,000 shares.
January 26, 2017 at 07:39 am
Share
Medy-Tox Inc. (KOSDAQ:A086900) announces a share repurchase program. Under the program, the company will repurchase up to 10,000 shares. The estimated price for repurchase would amount to KRW 4,083 million, which is based on the market close price of January 25, 2017. The shares will be repurchased directly on the Korea Securities Dealers Automated Quotation market. The purpose of the program is to provide stability and to enhance the shareholder's value of share price. The company's daily repurchase limit is 6,712 common shares. The program is valid until April 25, 2017. As of January 25, 2017, the company had 354,544 common shares in treasury under the dividend capacity and 1,506 common shares in treasury under other capacities.
Medy Tox Inc is a Korea-based company engaged in the development, manufacture and marketing of biopharmaceuticals. The Companyâs main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The Company provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The Company also engages in technology transfer. The Company distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.
MEDY-TOX INC. 
